Dengue
Drug research and approvals for dengue: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 24 studies of dengue are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 0 approved and 7 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 24
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 1
- Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and…NCT07706686 · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID) · starts Aug 7, 2026
- Gut Leakage' in DengueNCT07602920 · Not reported · University of Oxford · starts Aug 1, 2026
- A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)NCT07576868 · Phase 2 / Phase 3 · Hyundai Bioscience Co., Ltd. · starts Apr 9, 2026
- International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR)NCT07409857 · Not reported · Mahidol University · starts Dec 1, 2025
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveNCT07358910 · Not reported · Institut Pasteur du Cambodge · starts Dec 18, 2025
- Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic DiseasesNCT07087912 · Phase 4 · University of Sao Paulo General Hospital · starts Mar 16, 2026
- Immune Responses to Dengue and SepsisNCT07040202 · Not reported · Institut Pasteur du Cambodge · starts Jun 2, 2025
- Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)NCT07016321 · Phase 2 / Phase 3 · Johns Hopkins University · starts Sep 1, 2026
- Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus InfectionNCT07007585 · Not reported · Jose Ivan Rodriguez de Molina Serrano · starts Aug 1, 2025
Approved 2
- Dengue virus, live attenuatedBiological vaccine - induces immune response
- Chimeric yellow fever dengue virus, live attenuatedBiological vaccine - induces immune response
Phase 3 3
- Pertussis vaccine adsorbedBiological vaccine - induces immune response
- Diphtheria toxoidDiphtheria toxoid vaccine antigen
- Tetanus toxoidTetanus toxoid vaccine antigen
Phase 2 5
- ZanamivirNeuraminidase inhibitor
- IvermectinGlutamate-gated chloride channel modulator
- IC14Monocyte differentiation antigen CD14 inhibitor
- MelatoninMelatonin receptor agonist
- Mosnodenvir
Phase 1 or earlier 3
- CelgosivirAlpha glucosidase inhibitor
- Aluminum hydroxideAntacid
- Modipafant
How its trials ended
242 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 79 whose ending is known, 70% met their primary endpoint, 9% missed it and 22% stopped early.
- Completed, result not reported9840%
- Met its primary endpoint5523%
- Ongoing3916%
- Status unknown2611%
- Stopped: other or unclear125%
- Missed its primary endpoint73%
- Stopped: sponsor or business decision31%
- Stopped: lack of efficacy1<1%
- Stopped: enrollment or feasibility1<1%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Mar 11, 2022 | A phase 2, randomized, double-blind, multicenter study to evaluate the safety and immunogenicity of three different potency levels of V181 (dengue quadrivalent…V181 | Merck & Co. (MSD) | Ongoing |
| Dec 18, 2023 | A phosphoramidate oral prodrug of a unique 6-modified…Treatment of disease caused by dengue virus | Atea Pharmaceuticals Inc. | Designated |
| Jun 21, 2023 | Recombinant human IgG1 neutralizing monoclonal antibody…Treatment of dengue | AbViro LLC | Designated |
| Sep 1, 2021 | NafamostatTreatment of Dengue Fever | RNR Biomedical inc | Designated |
| Dec 26, 2017 | Arylalkyl 3-ketoindoleTreatment of dengue virus infection | Janssen Research & Development, LLC | Designated |
| May 18, 2016 | Liposomal glutathioneTreatment of Dengue Virus infection. | Your Energy Systems, LLC | Designated |
| Aug 6, 2013 | Conjugate of a dengue virus specific small chemical ligand…Treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome) | NanoViricides Incorporated | Designated |
| Mar 3, 2003 | Polyinosinic-polycytidilic acidTreatment of flavivirus infections including those due to West Nile, Japanese encephalitis, dengue, St. Louis encephalitis, yellow fever,… | Oncovir | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Dec 5, 2022 | QdengaDengue tetravalent vaccine (live, attenuated) | Takeda Pharmaceuticals International AG Ireland Branch | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA